The purpose of this study is to evaluate the safety and efficacy of niraparib in Japanese participants with platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who achieved complete response (CR) or partial response (PR) in the last chemotherapy containing platinum-based anticancer agents.
Active, not recruiting
Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| Niraparib | Niraparib 300 mg |
The drug being tested in this study is called niraparib. Niraparib is being tested to treat
people who have platinum-sensitive, relapsed ovarian cancer, fallopian tube cancer, or
primary peritoneal cancer. This study will look at the safety and efficacy of niraparib in
Japanese participants.
The study will enroll approximately 15 participants. Participants will be enrolled to one
group and after that will be asked to take niraparib capsules at the same time each day
throughout the study:
- Niraparib 300 mg
This multi-center trial will be conducted in Japan. The overall time to participate in this
study is approximately 28 months. Participants will make multiple visits to the clinic in the
treatment period, and the post-treatment period including follow-up assessments after the
last dose of the study drug.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Niraparib 300 mg | Experimental | Niraparib 300 mg, capsules, orally, once daily on Days 1 to 28 of each 28-day treatment Cycle (Up to 3 Cycles till data cut-off 17 March 2019). |
|
Inclusion Criteria
1. Japanese female participants aged 20 years or older on the day of signing informed
consent.
2. Voluntary written consent must be given before performance of any study related
procedure not part of standard medical care, with the understanding that consent may
be withdrawn by the participant at any time without prejudice to future medical care.
3. Participant must have a histologically diagnosed ovarian cancer, fallopian tube
cancer, or primary peritoneal cancer.
4. Participant must have a high-grade (or Grade 3) serous or high-grade predominantly
serous histology or known to have germline breast cancer gene mutation (gBRCAmut).
5. Participants must have completed at least 2 previous lines of platinum-containing
therapy (eg, carboplatin, oxaliplatin, or cisplatin):
Note: The last platinum regimen did not necessarily have to immediately follow the
next-to-last (penultimate) platinum regimen. For example, if a participant received a
non-platinum regimen between the penultimate platinum regimen and last platinum
regimen, she could have been eligible as long as she met all entry criteria.
1. For the penultimate platinum-based chemotherapy prior to study enrollment,
participants must have had platinum-sensitive disease after this treatment,
defined as achieving a response (CR or PR) and disease progression >6 months
after completion of her last dose of platinum therapy (documented 6 to 12 months
or >12 months). Source documentation was required.
2. For the last line of platinum-based chemotherapy prior to study enrollment:
- Participants must have received a platinum-containing regimen for a minimum
of 4 cycles.
- Participants must have achieved a partial or complete tumor response.
- Following the last regimen, participants must have had either: CA-125 in the
normal range, OR; CA-125 decrease by more than 90% during the last platinum
regimen, and which was stable for at least 7 days (ie, no increase >15%).
- Following the last regimen, participants could not have had any measurable
lesion >2 cm at the time of study enrollment.
3. Participants must have been enrolled within 8 weeks after completion of their
final dose of the platinum-containing regimen.
6. Participants must have performance status of ≤1 on the Eastern Cooperative Oncology
Group (ECOG) Performance Status Scale.
7. Participants must have adequate organ function as indicated by the following
laboratory values:
1. Absolute neutrophil count (ANC) ≥1,500/μL.
2. Platelet count ≥100,000/μL.
3. Hemoglobin ≥9 g/dL.
4. Serum creatinine ≤1.5× institutional upper limit of normal (ULN) OR calculated
creatinine clearance ≥50 mL/minute, using the Cockcroft-Gault equation.
5. Total bilirubin ≤1.5×ULN OR direct bilirubin ≤1×ULN.
6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN
unless liver metastases were present, in which case they had to be ≤5×ULN.
8. Participants must be able to take oral medications.
9. Female participants of childbearing potential must be negative for pregnancy test
(beta-human chorionic gonadotropin [β-hCG]) within 7 days prior to receiving the first
dose of study treatment.
10. Female participants who:
1. Are postmenopausal for at least 1 year before the screening visit, OR
2. Are surgically sterile, OR
3. If they are of childbearing potential, agree to practice 1 highly effective
method of contraception and 1 additional effective (barrier) method at the same
time, from the time of signing the informed consent through 180 days after the
last dose of study drug, OR
4. Agree to practice true abstinence, when this is in line with the preferred and
usual lifestyle of the participant. (Periodic abstinence [eg, calendar,
ovulation, symptothermal, postovulation methods], condoms only, withdrawal,
spermicides only, and lactational amenorrhea are not acceptable methods of
contraception. Female and male condoms should not be used together.)
Exclusion Criteria
1. Participants who have had drainage of ascites during last 2 cycles of last
chemotherapy.
2. Participants who have had palliative radiotherapy encompassing >20% of the bone marrow
within 1 week of the first dose of study treatment.
3. Participants who have any, persistent, Grade ≥3 toxicity from last cancer therapy.
4. Participants who have symptomatic, uncontrolled brain or leptomeningeal metastases. To
be considered "controlled," central nervous system (CNS) disease must have undergone
treatment (eg, radiation or chemotherapy) at least 1 month prior to study enrollment.
The participant must not have had any new or progressive signs or symptoms related to
the CNS disease and must have been taking a stable dose of steroids or no steroids (as
long as these were started at least 4 weeks prior to enrollment] or no steroids). A
scan to confirm the absence of brain metastases at baseline was not required.
Participants with spinal cord compression might have been considered if they had
received definitive treatment for this and evidence of clinically stable disease for
28 days.
5. Participants who have known hypersensitivity to the components of niraparib.
6. Participants who have had prior treatment with a known poly (adenosine diphosphate
[ADP]-ribose) polymerase (PARP) inhibitor.
7. Participant who have had treatment with any investigational products within 28 days or
5 half-lives (whichever was longer) before the first dose.
8. Participants who have had major surgery per Investigator judgment within 3 weeks of
the first dose. Participant must have recovered from any effects of any major surgery.
9. Participants who have diagnosis, detection, or treatment of invasive second primary
malignancy other than ovarian cancer ≤24 months prior to study enrollment (except
basal or squamous cell carcinoma of the skin that was definitively treated). Note:
Participants must not have any known history or current diagnosis of myelodysplastic
syndrome (MDS) or acute myeloid leukemia (AML), irrespective of the time for disease
history.
10. Participants who are considered a poor medical risk due to a serious, uncontrolled
medical disorder, non-malignant systemic disease, or active, uncontrolled infection.
Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent
(within 90 days of the first dose) myocardial infarction, uncontrolled major seizure
disorder, unstable spinal cord compression, superior vena cava syndrome, small bowel
obstruction or other serious gastrointestinal disorder, or any psychiatric disorder
that prohibits obtaining informed consent.
11. Participants who have received a transfusion (platelets or red blood cells) within 4
weeks of the first dose of study treatment.
12. Participants who have received a live virus or bacterial vaccines within 4 weeks of
the first dose of study treatment.
13. Participants who have a history or current evidence of any condition, therapy, or lab
abnormality (including active or uncontrolled myelosuppression [ie, anemia,
leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the
study, interfere with the participant's participation throughout the study period, or
study participation is not in the best interest of the participant.
14. Participants who are regular user (including "recreational use") of any illicit drugs
at the time of signing informed consent or have a recent history (within the past
year) of drug or alcohol abuse.
15. Participants who are pregnant or breast-feeding, or expecting to conceive within the
planned duration of the study.
NOTE: If a breast-feeding woman discontinue breast-feeding, she may be enrolled in the
study.
16. Participants who are immunocompromised (participants with splenectomy are allowed).
17. Participants who have known human immunodeficiency virus (HIV) positive.
18. Participants who have known hepatitis B surface antigen (HBsAg) positive, or known or
suspected active hepatitis C virus (HCV) infection.
NOTE: Participants who are positive for hepatitis B core antibody (HBcAb) or hepatitis B
surface antibody (HBsAb) can be enrolled but must have an undetectable hepatitis B virus
(HBV) viral load. Participants who have positive hepatitis C virus antibody (HCVAb) must
have an undetectable HCV viral load.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 20 Years |
| Eligible Gender: | Female |
| Healthy Volunteers: | No |
| Measure: | Number of Participants With Grade 3 or 4 Thrombocytopenia Occurring Within 30 Days After Initial Administration of Niraparib |
| Time Frame: | Up to 30 days after the first dose |
| Safety Issue: | |
| Description: | An adverse event of 'thrombocytopenia' was collected and graded as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03.As per the NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to Adverse Events (AE). |
| Measure: | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. |
| Measure: | Number of Participants With Grade 3 or Higher TEAEs |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A severity grade is defined by the NCI-CTCAE Version 4.03. As per NCI-CTCAE, Grade 1 scales as Mild; Grade 2 scales as Moderate; Grade 3 scales as severe or medically significant but not immediately life threatening; Grade 4 scales as life-threatening consequences; and Grade 5 scales as death related to AE. |
| Measure: | Number of Participants With Serious Adverse Events (SAEs) |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event. |
| Measure: | Number of Participants With TEAEs Leading to Drug Discontinuation |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
| Measure: | Number of Participants With TEAEs Leading to Dose Interruption |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
| Measure: | Number of Participants With TEAEs Leading to Dose Reduction |
| Time Frame: | Up to 30 days after the last dose (Approximately 4 months) |
| Safety Issue: | |
| Description: | An AE is defined as any untoward medical occurrence in a participant who has enrolled in a study; it does not necessarily have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. |
| Measure: | Progression Free Survival (PFS) |
| Time Frame: | Until disease progression, death or data cut-off (Approximately 4 months) |
| Safety Issue: | |
| Description: | PFS is defined as the time in months from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per RECIST 1.1, PD is defined as at least a 20% increase in the SoD (Sum of Diameters) of target lesions, taking as a reference the smallest (nadir) SoD since (and including) baseline. In addition to the relative increase of 20%, the SoD must also demonstrate an absolute increase of at least 5 mm. |
| Measure: | Overall Survival (OS) |
| Time Frame: | Up to data cut-off (approximately 4 months) |
| Safety Issue: | |
| Description: | OS is defined as the time from the study enrollment to death due to any cause. |
| Measure: | Overall Response Rate (ORR) |
| Time Frame: | Up to approximately 4 months |
| Safety Issue: | |
| Description: | ORR is defined as the proportion of participants achieving Complete Response (CR) or Partial Response (PR) as assessed by the investigator per RECIST (v.1.1). Per RECIST 1.1, CR is defined as disappearance of all target lesions; PR is defined as atleast 30% decrease in sum of diameters (SoD) of target lesions. |
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Active, not recruiting |
| Lead Sponsor: | Takeda |
January 13, 2021
